Treating coronary heart disease in kidney failure patients

November 29, 2012

Among the two available procedures for opening blocked arteries surrounding the heart, one appears to be safer than the other for dialysis patients, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The findings may help lead to better care for kidney failure patients with coronary heart disease.

While 30% to 60% of kidney failure patients on dialysis have blocked arteries surrounding the heart, there is little information regarding how to optimally fix the life-threatening problem in these individuals. That's because dialysis patients have been excluded from clinical trials on the two available procedures: (, or CABG) and angioplasty (percutaneous coronary intervention, or PCI).

Tara Chang, MD, Wolfgang Winkelmayer, MD, ScD (Stanford University School of Medicine) and their colleagues examined a database of all patients on dialysis in the United States with primary to determine which is the best revascularization strategy: CABG or PCI. They identified nearly 22,000 who underwent CABG or PCI between 1997 and 2009.

Among the major findings:

  • Overall survival rates were poor, with five-year survival rates of 22% to 25% irrespective of revascularization strategy. (Five-year survival rates in patients without kidney disease are over 90%.)
  • CABG was associated with a 13% lower risk of death and a 12% lower risk of either dying or having a heart attack.
"It is important to note that because our study was observational, our results cannot prove that CABG is better; only a randomized trial can do that," said Dr. Chang. "However, our study does offer guidance to patients and providers who must make these tough decisions and suggests that in carefully selected patients on dialysis with multivessel , CABG may be preferred rather than PCI." Because organizing a randomized trial of CABG and PCI in patients on dialysis would be quite difficult, observational studies such as this one may be the best way to compare the two strategies.

Explore further: CABG still preferred over PCI in patients with triple vessel disease

More information: The article, entitled "Multivessel Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention in ESRD," will appear online at jasn.asnjournals.org/ on November 29, 2012.

Related Stories

Increased stroke risk at 30-days post-CABG versus PCI

August 21, 2012

(HealthDay) -- The risk of stroke at 30 days is significantly higher in patients who undergo coronary revascularization with coronary artery bypass graft (CABG) surgery compared to those who undergo percutaneous coronary ...

Recommended for you

Bile acid uptake inhibitor prevents NASH / fatty liver in mice

September 21, 2016

Drugs that interfere with bile acid recycling can prevent several aspects of NASH (nonalcoholic steatohepatitis) in mice fed a high-fat diet, scientists from Emory University School of Medicine and Children's Healthcare of ...

New therapeutic target for Crohn's disease

September 20, 2016

Research from the Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies a promising new target for future drugs to treat inflammatory bowel disease (IBD). The study, published today in Cell Reports, also indicates ...

Mosquitoes, Zika and biotech regulation

September 19, 2016

In a new Policy Forum article in Science, NC State professor Jennifer Kuzma argues that federal authorities are missing an opportunity to revise outdated regulatory processes not fit for modern innovations in biotechnology, ...

Arthritis drug may help with type of hair loss

September 22, 2016

(HealthDay)—For people who suffer from a condition that causes disfiguring hair loss, a drug used for rheumatoid arthritis might regrow their hair, a new, small study suggests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.